Related Experiment Video
Updated: Feb 11, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Sacubitril/Valsartan: From Clinical Trials to Real-world Experience
Joanna M Joly1, Akshay S Desai2
1Cardiovascular Division, Brigham & Women's Hospital, 75 Francis St., Boston, MA, 02115, USA.
Insights
Sacubitril/valsartan significantly reduces cardiovascular death and heart failure progression in patients with heart failure with reduced ejection fraction (HFrEF). Real-world data confirm its safety and efficacy, supporting guideline updates.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure with reduced ejection fraction (HFrEF) remains a significant cause of morbidity and mortality.
- Angiotensin-receptor neprilysin inhibitors represent a novel therapeutic class for HFrEF management.
Purpose of the Study:
- To review the real-world clinical experience with sacubitril/valsartan in HFrEF patients.
- To discuss the evidence supporting guideline updates favoring sacubitril/valsartan over ACE inhibitors or ARBs.
Main Methods:
- Review of clinical trials and real-world data on sacubitril/valsartan.
- Analysis of updated clinical practice guidelines.
Main Results:
- Sacubitril/valsartan demonstrates substantial reductions in cardiovascular mortality and HFrEF progression compared to enalapril.
- A growing body of evidence supports the safety and efficacy of sacubitril/valsartan across diverse HFrEF patient populations.
Conclusions:
- Sacubitril/valsartan is recommended in updated guidelines for selected HFrEF patients.
- Practical strategies for patient selection and utilization are discussed.
- Areas requiring future research are identified.
Purpose Of Review:
Compared to enalapril, use of angiotensin-receptor blocker and neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced ejection fraction (HFrEF) is associated with substantial reductions in both cardiovascular mortality and heart failure progression. The purpose of this review is to discuss the real-world experience of sacubitril/valsartan.
Recent Findings:
In the years following the publication of the landmark PARADIGM-HF trial in 2014 and its subsequent FDA approval, a growing evidence base supports the safety and efficacy of sacubitril/valsartan in a broad spectrum of patients with HFrEF. Updated clinical practice guidelines have embraced the use of sacubitril/valsartan in preference to ACE inhibitors or ARBs in selected patients. In this review, we highlight the clinical trials that led to these key updates to clinical guidelines, offer practical strategies for patient selection and utilization in clinical practice, and identify important areas of uncertainty that require future research.
More Related Videos
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
What is an Experiment?
Thomson's e/m Experiment
A particle with charge q, speed v, and mass m enters an area from the top, where the magnetic and electric fields are perpendicular both to the particle's motion and to one another. The magnetic...